JP2001503385A - ポリヌクレオチド送達のための組成物および方法 - Google Patents
ポリヌクレオチド送達のための組成物および方法Info
- Publication number
- JP2001503385A JP2001503385A JP50831998A JP50831998A JP2001503385A JP 2001503385 A JP2001503385 A JP 2001503385A JP 50831998 A JP50831998 A JP 50831998A JP 50831998 A JP50831998 A JP 50831998A JP 2001503385 A JP2001503385 A JP 2001503385A
- Authority
- JP
- Japan
- Prior art keywords
- polynucleotide
- polycationic
- polycationic agent
- agent
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/858—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from apolipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Obesity (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Dermatology (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.以下の式: を有するポリカチオン性薬剤であって、ここで、 nは、10〜100の整数であり; 以下の各モノマーについてのR1、R2、およびR3は、 1〜200ダルトンの分子量を有する部分から独立して選択され; TaおよびTcは末端基であり; R1は、少なくとも1つのモノマーについて水素ではなく; ここで、該ポリカチオン性薬剤は、末端基を除いて、少なくとも25%の正に荷 電したモノマーを含み、そして ここで、該ポリカチオン性薬剤は、生理学的pHにて、正味の正電荷を示す、薬 剤。 2.前記ポリカチオン性薬剤が繰り返しのトリマーを含む、請求項1に記載のポ リカチオン性薬剤。 3.各トリマー中の2つのR1基が中性部分であり、そして各トリマー中の1つ のR1基がカチオン性部分である、請求項2に記載のポリカチオン性薬剤。 4.R1が正に帯電した部分、負に帯電した部分、および中性部分からなる群か ら選択される、請求項1に記載のポリカチオン性薬剤。 5.R1が、アミノ酸上で見出される置換基から選択される、請求項1に記載の ポリカチオン性薬剤。 6.R1が、芳香族および脂肪族基からなる群から選択される、請求項1に記載 のポリカチオン性薬剤。 7.少なくとも1つのR1が、アルキルアンモニウム、アミノアルキル、グアニ ジノアルキル、アミジノアルキル、アミノシクロヘキシル、ピペリジル、グアニ ジノベンジル、アミジノベンジル、ピリジルメチル、アミノベンジル、アルキル フェニル(alkyphenyl)、インドリルアルキル、アルコキシフェニルアルキル、ハ ロフェニルアルキル、およびヒドロキシフェニルアルキルからなる群より選択さ れる、請求項1に記載のポリカチオン性薬剤。 8.前記カチオン性部分がアミノエチルである、請求項3に記載のポリカチオン 性薬剤。 9.前記中性部分が、フェネチル、ベンジル、フェニルプロピル、(R)α-メチル ベンジル、(S)α-メチルベンジル、メトキシフェネチル、およびクロロフェネチ ルからなる群より選択される、請求項8に記載のポリカチオン性薬剤。 10.R1およびR3が少なくとも1つのモノマーについて両方水素である、請求 項1に記載のポリカチオン性薬剤。 11.nが36である、請求項10に記載のポリカチオン性薬剤。 12.nが24である、請求項10に記載のポリカチオン性薬剤。 13.nが18である、請求項10に記載のポリカチオン性薬剤。 14.nが12である、請求項10に記載のポリカチオン性薬剤。 15.TaおよびTcが、ポリペプチド、脂質、リポタンパク質、ビタミン、ホルモ ン、ポリアルキレン(polyakylene)グリコール、およびサッカライドからなる群 より選択される末端基である、請求項8に記載のポリカチオン性薬剤。 16.以下: (i)ポリヌクレオチド;および (ii)前記ポリカチオン性薬剤が、ポリヌクレオチドの細胞への侵入を媒介し得 る、請求項1に記載のポリカチオン性薬剤、 を含む、組成物。 17.以下: (i)薬学的に受容可能なキャリア; (ii)治療有効量のポリヌクレオチド;および (iii)請求項1に記載のポリカチオン性薬剤の前記ポリヌクレオチドを中和す るに有効な量、を含む薬学的組成物であって、ここで該ポリカチオン性薬剤は、 ポリヌクレオチドの細胞への侵入を媒介し得る薬剤である、薬学的組成物。 18.ポリヌクレオチドをポリカチオン性薬剤と複合体化する方法であって、以 下: (i)ポリヌクレオチドを提供する工程;および (ii)該ポリヌクレオチドを、請求項1に記載のポリカチオン性薬剤と接触させ る工程であって、ここで該ポリカチオン性薬剤は、ポリヌクレオチドの細胞への 侵入を媒介し得る、工程、 を包含する、方法。 19.ポリヌクレオチドを縮合させる方法であって、以下: ポリヌクレオチドを、縮合する量の請求項1に記載のポリカチオン性薬剤と接触 させる工程であって、該縮合する量が、該ポリヌクレオチドのサイズを減少させ るに十分なポリカチオン性薬剤の量である、工程、 を包含する、方法。 20.ポリヌクレオチドの血清分解を阻害する方法であって、ポリヌクレオチド を、請求項1に記載のポリカチオン性薬剤と接触させる工程であって、該ポリカ チオン性薬剤が、少なくとも10分で血清分解を阻害するに有効な量で存在する工 程、を包含する、方法。 21.以下: (i)リポタンパク質; (ii)ポリヌクレオチド結合分子;および (iii)ポリヌクレオチド を含む組成物であって、ここで該組成物は、細胞へのポリヌクレオチド取り込み の頻度を増加させ得る、組成物。 22.前記リポタンパク質が、高密度リポタンパク質、中間密度リポタンパク質 、低密度リポタンパク質、および非常に低密度なリポタンパク質からなる群より 選択される、請求項21に記載の組成物。 23.前記リポタンパク質が、高密度リポタンパク質、中間密度リポタンパク質 、低密度リポタンパク質、および非常に低密度なリポタンパク質からなる群より 選択されるタンパク質の変異体、フラグメント、または融合物である、請求項2 1に記載の組成物。 24.前記リポタンパク質がアセチル化された低密度リポタンパク質である、請 求項21に記載の組成物。 25.以下: (a)のポリヌクレオチド; (b)該ポリヌクレオチドの負電荷を中和するに有効な量のポリヌクレオチド結 合分子;および (c)治療有効量のリポタンパク質 を含む、薬学的組成物。 26.前記ポリヌクレオチドがポリカチオン性薬剤である、請求項25に記載の 薬学的組成物。 27.ポリヌクレオチドの細胞への侵入を容易にするための組成物を生成する方 法であって、以下: (i)ポリヌクレオチドを提供する工程 (ii)該ポリヌクレオチドを中和するに有効な量で、ポリヌクレオチド結合分子 を提供する工程; (ii)該ポリヌクレオチドと、該ポリヌクレオチド結合分子を接触させ、複合体 を形成する工程; (iii)リポタンパク質を提供する工程;次いで (iv)該複合体を、該リポタンパク質と接触させる工程 を包含する、方法。 28.細胞へのポリペプチド取り込みの頻度を増加させる方法であって、以下: (i)(a)治療有効量のポリヌクレオチド; (b)該ポリヌクレオチドを中和するに有効な量のポリヌクレオチド結合分子 ;および (c)有効量のリポタンパク質 を含む組成物を提供する工程;次いで (ii)該組成物を該細胞に接触させる工程 を包含する、方法。 29.細胞へのポリヌクレオチド取り込みの頻度を増加させる方法であって、以 下: (i)(a)ポリヌクレオチド;および (b)該ポリヌクレオチドの負電荷を中和するに有効な量の請求項1に記載の ポリカチオン性薬剤 を含む組成物を提供する工程;次いで (ii)該組成物を該細胞に接触させる工程 を包含する、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2386796P | 1996-08-13 | 1996-08-13 | |
US60/023,867 | 1996-08-13 | ||
PCT/US1997/014465 WO1998006437A2 (en) | 1996-08-13 | 1997-08-13 | Compositions and methods for polynucleotide delivery |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006086765A Division JP2006257088A (ja) | 1996-08-13 | 2006-03-27 | ポリヌクレオチド送達のための組成物および方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001503385A true JP2001503385A (ja) | 2001-03-13 |
JP4320054B2 JP4320054B2 (ja) | 2009-08-26 |
Family
ID=21817661
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50831998A Expired - Fee Related JP4320054B2 (ja) | 1996-08-13 | 1997-08-13 | ポリヌクレオチド送達のための組成物および方法 |
JP2006086765A Withdrawn JP2006257088A (ja) | 1996-08-13 | 2006-03-27 | ポリヌクレオチド送達のための組成物および方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006086765A Withdrawn JP2006257088A (ja) | 1996-08-13 | 2006-03-27 | ポリヌクレオチド送達のための組成物および方法 |
Country Status (7)
Country | Link |
---|---|
US (3) | US6251433B1 (ja) |
EP (1) | EP0941122B1 (ja) |
JP (2) | JP4320054B2 (ja) |
AT (1) | ATE252914T1 (ja) |
CA (1) | CA2264012C (ja) |
DE (1) | DE69725878T2 (ja) |
WO (1) | WO1998006437A2 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2006001122A1 (ja) * | 2004-06-24 | 2008-04-17 | 株式会社ディナベック研究所 | Rnaウイルスが導入された樹状細胞を含む抗癌剤 |
JP2011504874A (ja) * | 2007-11-28 | 2011-02-17 | 国立大学法人 東京医科歯科大学 | 内因性カイロミクロンを利用した、標的遺伝子の発現を抑制する核酸のデリバリーシステム |
WO2012147370A1 (ja) * | 2011-04-28 | 2012-11-01 | 国立大学法人山口大学 | ターミネータ配列を含む高発現用リバースプライマー及びリニアdna |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0872552A1 (en) * | 1997-04-15 | 1998-10-21 | Leadd B.V. | A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or Apoptin |
US20020052310A1 (en) * | 1997-09-15 | 2002-05-02 | Massachusetts Institute Of Technology The Penn State Research Foundation | Particles for inhalation having sustained release properties |
US6652837B1 (en) | 1996-05-24 | 2003-11-25 | Massachusetts Institute Of Technology | Preparation of novel particles for inhalation |
CN1177934C (zh) * | 1997-04-28 | 2004-12-01 | 阿文蒂斯药物股份有限公司 | 腺病毒介导的肿瘤内投送血管生成拮抗剂用于肿瘤的治疗 |
US6197332B1 (en) | 1997-08-13 | 2001-03-06 | Chiron Corporation | Lipid-conjugated polyamide compounds and related compositions and methods thereof |
US6818627B1 (en) * | 1997-08-14 | 2004-11-16 | The Trustees Of The University Of Pennsylvania | Functional fragments of HIV-1 Vpr protein and methods of using the same |
US7135191B2 (en) * | 1997-09-04 | 2006-11-14 | Zsolt Istvan Hertelendy | Urogenital or anorectal transmucosal vaccine delivery system |
US7052678B2 (en) | 1997-09-15 | 2006-05-30 | Massachusetts Institute Of Technology | Particles for inhalation having sustained release properties |
WO1999056784A2 (en) * | 1998-05-06 | 1999-11-11 | Transgene S.A. | Inprovements in gene therapy using compositions comprising a polynucleotide and a nuclease inhibitor or interleukin-10 |
EP0967289A1 (en) * | 1998-05-06 | 1999-12-29 | Transgene S.A. | Improvements in gene therapy using compositions comprising a polynucleotide and a nuclease inhibitor |
ATE274923T1 (de) * | 1998-06-10 | 2004-09-15 | Biognostik Ges | Stimulierung des immunsystems |
US20070010004A1 (en) * | 1998-07-20 | 2007-01-11 | Monahan Sean D | Micellar systems |
DE19858005B4 (de) * | 1998-12-16 | 2007-02-08 | november Aktiengesellschaft, Gesellschaft für Molekulare Medizin | Synthetisches Nucleinsäure-Partikel |
US7368261B1 (en) | 1999-04-30 | 2008-05-06 | Novartis Vaccines And Diagnostics Srl | Conserved Neisserial antigens |
GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
US6677445B1 (en) | 1999-08-27 | 2004-01-13 | Chiron Corporation | Chimeric antisense oligonucleotides and cell transfecting formulations thereof |
ES2559317T3 (es) | 1999-10-29 | 2016-02-11 | Glaxosmithkline Biologicals Sa | Péptidos antigénicos de Neisseria |
DE60142772D1 (de) | 2000-01-17 | 2010-09-23 | Novartis Vaccines & Diagnostic | Membranvesikel (omv) impfstoff, der n. meningitidis serogruppe b membranproteine enthält |
WO2001062144A1 (en) * | 2000-02-25 | 2001-08-30 | Health Research, Inc. | Method for transdermal sampling of analytes |
EP1950297A2 (en) | 2000-05-31 | 2008-07-30 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
CA2410516A1 (en) | 2000-05-31 | 2001-12-06 | Chiron Corporation | Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
EP1953243B1 (en) | 2000-06-15 | 2012-12-26 | Novartis Vaccines and Diagnostics, Inc. | Polynucleotides related to colon cancer |
EP2277894A1 (en) | 2000-10-27 | 2011-01-26 | Novartis Vaccines and Diagnostics S.r.l. | Nucleic acids and proteins from streptococcus groups A & B |
JP2005502309A (ja) * | 2000-12-23 | 2005-01-27 | カイロン コーポレイション | オリゴヌクレオチドトランスフェクションスクリーニング方法 |
AU2002230993B2 (en) * | 2000-12-29 | 2006-02-02 | Alkermes, Inc. | Particles for inhalation having sustained release properties |
GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
WO2002094871A1 (en) * | 2001-05-24 | 2002-11-28 | Human Dna Technology Inc | Novel keratinocyte growth factor-2 analogue in hair follicle |
JP2004537596A (ja) * | 2001-08-03 | 2004-12-16 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | オリゴグアニジン輸送因子の二方向合成 |
US20060264608A1 (en) * | 2001-08-03 | 2006-11-23 | Wender Paul A | Bi-directional synthesis of oligoguanidine transport agents |
JP2005538035A (ja) * | 2001-12-11 | 2005-12-15 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | グアニジニウム輸送試薬および結合体 |
MXPA04005713A (es) * | 2001-12-11 | 2005-06-06 | Baylor College Medicine | Complemento de la hormona de liberacion de la hormona de crecimiento para tratar sujetos cronicamente enfermos. |
US6899892B2 (en) * | 2001-12-19 | 2005-05-31 | Regents Of The University Of Minnesota | Methods to reduce body fat |
US20040043003A1 (en) * | 2002-01-31 | 2004-03-04 | Wei Chen | Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions |
US20040009937A1 (en) * | 2002-01-31 | 2004-01-15 | Wei Chen | Methods and composition for delivering nucleic acids and/or proteins to the respiratory system |
US20050075298A1 (en) * | 2002-01-31 | 2005-04-07 | Wei Chen | Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa |
KR20030068337A (ko) * | 2002-02-15 | 2003-08-21 | 사회복지법인삼성생명공익재단(삼성서울병원) | 유전자치료용 진핵발현벡터 |
WO2003078576A2 (en) * | 2002-03-12 | 2003-09-25 | Nitto Denko Corporation | Vector for transfection of eukaryotic cells |
EP1485196A1 (en) * | 2002-03-20 | 2004-12-15 | Rhodia Inc. | Vesicles comprising an amphiphilic di-block copolymer and a hydrophobic compound. |
AU2003221733A1 (en) * | 2002-04-17 | 2003-11-03 | University Of Florida Research Foundation, Inc. | Improved raav vectors |
KR100505434B1 (ko) * | 2002-08-31 | 2005-08-05 | 한국과학기술연구원 | 생리활성물질을 효과적으로 전달하기 위한 요오드화 오일과 양이온성 고분자를 이용한 제제 및 이들의 제조방법 |
EP1562982B1 (en) | 2002-11-15 | 2010-05-05 | Novartis Vaccines and Diagnostics S.r.l. | Unexpected surface proteins in neisseria meningitidis |
US7682626B2 (en) * | 2003-02-07 | 2010-03-23 | Roche Madison Inc. | Polyvinylethers for delivery of polynucleotides to mammalian cells |
GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
US20050031579A1 (en) * | 2003-06-30 | 2005-02-10 | Canji, Inc. | Polymer encapsulation of adenoviruses |
US20060035242A1 (en) * | 2004-08-13 | 2006-02-16 | Michelitsch Melissa D | Prion-specific peptide reagents |
WO2005069791A2 (en) * | 2004-01-08 | 2005-08-04 | Cedars-Sinai Medical Center | Compositions and methods for enhancing the th1 response in connection with dendritic cell vaccines |
WO2006076342A2 (en) * | 2005-01-11 | 2006-07-20 | Heart Failure Technologies, Inc. | Method and system for treating heart failure |
MX2007008497A (es) * | 2005-01-13 | 2007-09-14 | Novartis Vaccines & Diagnostic | Ensayos inmunosorbentes enlazados a enzimas usando reactivos de peptidos especificos de prion. |
WO2006076683A2 (en) * | 2005-01-13 | 2006-07-20 | Novartis Vaccines And Diagnostics Inc. | Isolation and detection of pathogenic prions |
EP1848830A4 (en) * | 2005-01-13 | 2009-05-06 | Novartis Vaccines & Diagnostic | ISOLATION OF PATHOGENIC PRIONS |
US20070031512A1 (en) * | 2005-08-03 | 2007-02-08 | Amcol International Corporation | Virus-interacting layered phyllosilicates and methods of inactivating viruses |
US20080184618A1 (en) * | 2005-08-03 | 2008-08-07 | Amcol International | Virus-Interacting Layered Phyllosilicates and Methods of Use |
US20100272769A1 (en) * | 2005-08-03 | 2010-10-28 | Amcol International | Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use |
NZ594844A (en) | 2005-09-09 | 2013-04-26 | Novartis Ag | Prion-specific peptoid reagents |
CA2628300C (en) | 2005-11-02 | 2018-04-17 | Protiva Biotherapeutics, Inc. | Modified sirna molecules and uses thereof |
US20080090760A2 (en) * | 2005-12-09 | 2008-04-17 | Todd Hembrough | Compositions and Methods for Inhibiting Cellular Proliferation |
US9494593B2 (en) * | 2005-12-14 | 2016-11-15 | Chung Yuan Christian University | Method for separating nanoparticles with a controlled number of active groups |
WO2007095152A2 (en) * | 2006-02-10 | 2007-08-23 | The Regents Of The University Of California | TRANSDUCIBLE DELIVERY OF sIRNA BY dsRNA BINDING DOMAIN FUSIONS TO PTD/CPPS |
PL2054431T3 (pl) | 2006-06-09 | 2012-07-31 | Novartis Ag | Konformery adhezyn bakteryjnych |
CN101506368B (zh) * | 2006-07-12 | 2017-02-08 | 加利福尼亚大学董事会 | 通过可逆的磷酸三酯电荷中和保护基转导运输核酸 |
ATE544869T1 (de) * | 2006-08-30 | 2012-02-15 | Bioventures Inc | Verfahren und substanzen zur isolierung und erkennung kleiner polynukleotide |
WO2009009441A2 (en) * | 2007-07-06 | 2009-01-15 | Cedars-Sinai Medical Center | Self-assembling complex for targeting chemical agents to cells |
WO2009006680A1 (en) * | 2007-07-06 | 2009-01-15 | Sydney West Area Health Service | Epitopes of herpes simplex virus |
US9006191B2 (en) | 2007-12-27 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Silencing of polo-like kinase expression using interfering RNA |
AU2009236219B8 (en) | 2008-04-15 | 2015-06-25 | Arbutus Biopharma Corporation | Silencing of CSN5 gene expression using interfering RNA |
BRPI0910550A2 (pt) * | 2008-04-30 | 2015-09-29 | Novartis Ag | ensaio para confôrmeros patogênicos |
US8840881B2 (en) * | 2008-08-28 | 2014-09-23 | Aduro Gvax Inc. | Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer |
WO2010129853A2 (en) * | 2009-05-07 | 2010-11-11 | The Regents Of The University Of California | TRANSDUCIBLE DELIVERY OF NUCLEIC ACIDS USING MODIFIED dsRNA BINDING DOMAINS |
EP2446034A4 (en) * | 2009-06-22 | 2013-11-27 | Ipca Lab Ltd | NOVEL POLYNUCLEOTIDE MOLECULES FOR IMPROVED GENE EXPRESSION |
EP2582387A2 (en) | 2010-06-17 | 2013-04-24 | The United States Of America As Represented By The Secretary, National Institutes Of Health | Compositions and methods for treating inflammatory conditions |
US8981025B2 (en) | 2011-02-10 | 2015-03-17 | Corning Incorporated | Polymerizable catonic peptide monomers and polymers |
WO2013075132A1 (en) | 2011-11-17 | 2013-05-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Therapeutic rna switches compositions and methods of use |
US9035039B2 (en) | 2011-12-22 | 2015-05-19 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing SMAD4 |
MX367842B (es) | 2012-02-07 | 2019-09-09 | Global Bio Therapeutics Inc | Método compartimentado de administración de ácidos nucleicos y composiciones y usos del mismo. |
AU2013204327B2 (en) | 2012-04-20 | 2016-09-01 | Aviagen | Cell transfection method |
IN2015DN01765A (ja) | 2012-08-20 | 2015-05-29 | Univ California | |
US20140256639A1 (en) * | 2013-02-14 | 2014-09-11 | The Regents Of The University Of California | Peptoid neutralizing agents |
JP6293892B2 (ja) | 2013-08-08 | 2018-03-14 | グローバル・バイオ・セラピューティクス・インコーポレイテッドGlobal Bio Therapeutics,Inc. | 低侵襲処置用インジェクションデバイスおよびその使用 |
DK3030163T3 (da) | 2013-08-08 | 2019-07-01 | Global Bio Therapeutics Inc | Klemmeindretning til minimalt invasive procedurer |
US10415037B2 (en) | 2014-10-02 | 2019-09-17 | Arbutus Biopharma Corporation | Compositions and methods for silencing hepatitis B virus gene expression |
US20180245074A1 (en) | 2015-06-04 | 2018-08-30 | Protiva Biotherapeutics, Inc. | Treating hepatitis b virus infection using crispr |
WO2017019891A2 (en) | 2015-07-29 | 2017-02-02 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing hepatitis b virus gene expression |
JP7011830B2 (ja) | 2015-10-14 | 2022-01-27 | エックス-サーマ インコーポレイテッド | 氷晶形成を低減するための組成物および方法 |
US9758786B2 (en) | 2016-02-09 | 2017-09-12 | Autotelic, Llc | Compositions and methods for treating pancreatic cancer |
JP2019532027A (ja) | 2016-08-17 | 2019-11-07 | ソルスティス バイオロジクス,リミティッド | ポリヌクレオチド構築物 |
EP3645546A4 (en) | 2017-06-30 | 2021-12-01 | Solstice Biologics, Ltd. | CHIRAL PHOSPHORAMIDITIS AUXILIARIES AND THEIR METHODS OF USE |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235886A (en) * | 1979-10-31 | 1980-11-25 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
US5041497A (en) * | 1989-04-10 | 1991-08-20 | Allied-Signal Inc. | Process for preparing co-poly(amides/peptides) |
IE66205B1 (en) | 1990-06-14 | 1995-12-13 | Paul A Bartlett | Polypeptide analogs |
NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
DE4139001A1 (de) | 1991-11-27 | 1993-06-03 | Boehringer Mannheim Gmbh | Verfahren zur einschleusung von nukleinsaeuren in zellen |
US5334761A (en) * | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
BR9307092A (pt) | 1992-09-24 | 1999-03-30 | Chiron Corp | Processo para sintetizar monômero de poliamida n-substituida oligômero mistura de pelo menos dois oligômeros diferentes poli (n-substituida glicina) processo de tratamento anti-sentido composição processo de sintetizar composto de poliamida composto e processo para preparar mistura de compostos de amida |
CA2163364C (en) * | 1993-07-14 | 2009-10-27 | Francis C. Szoka, Jr. | Self-assembling polynucleotide delivery system comprising dendrimer polycations |
JPH10501963A (ja) | 1994-04-15 | 1998-02-24 | ターゲテッド ジェネティクス コーポレイション | 遺伝子送達融合タンパク質 |
US5670347A (en) | 1994-05-11 | 1997-09-23 | Amba Biosciences Llc | Peptide-mediated gene transfer |
US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
US5635487A (en) * | 1994-12-29 | 1997-06-03 | Wolff; Jon A. | Amphipathic, micellar delivery systems for biologically active polyions |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
EP0827406A1 (en) | 1995-03-08 | 1998-03-11 | The Scripps Research Institute | Carbopeptoids and carbonucleotoids |
US6120794A (en) | 1995-09-26 | 2000-09-19 | University Of Pittsburgh | Emulsion and micellar formulations for the delivery of biologically active substances to cells |
WO1997012052A1 (en) | 1995-09-28 | 1997-04-03 | Targeted Genetics Corporation | Transduction of hematopoietic cells by viral vector and a cationic lipid |
US5925333A (en) * | 1995-11-15 | 1999-07-20 | Massachusetts Institute Of Technology | Methods for modulation of lipid uptake |
DE19547648A1 (de) * | 1995-12-20 | 1997-06-26 | Hoechst Ag | Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate |
US5679559A (en) * | 1996-07-03 | 1997-10-21 | University Of Utah Research Foundation | Cationic polymer and lipoprotein-containing system for gene delivery |
-
1997
- 1997-08-13 US US08/910,647 patent/US6251433B1/en not_active Expired - Lifetime
- 1997-08-13 AT AT97938367T patent/ATE252914T1/de not_active IP Right Cessation
- 1997-08-13 WO PCT/US1997/014465 patent/WO1998006437A2/en active IP Right Grant
- 1997-08-13 CA CA2264012A patent/CA2264012C/en not_active Expired - Fee Related
- 1997-08-13 DE DE69725878T patent/DE69725878T2/de not_active Expired - Lifetime
- 1997-08-13 EP EP97938367A patent/EP0941122B1/en not_active Expired - Lifetime
- 1997-08-13 JP JP50831998A patent/JP4320054B2/ja not_active Expired - Fee Related
-
2000
- 2000-07-21 US US09/620,925 patent/US6468986B1/en not_active Expired - Fee Related
-
2002
- 2002-10-22 US US10/278,751 patent/US7462592B2/en not_active Expired - Fee Related
-
2006
- 2006-03-27 JP JP2006086765A patent/JP2006257088A/ja not_active Withdrawn
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2006001122A1 (ja) * | 2004-06-24 | 2008-04-17 | 株式会社ディナベック研究所 | Rnaウイルスが導入された樹状細胞を含む抗癌剤 |
JP2013151523A (ja) * | 2004-06-24 | 2013-08-08 | Dnavec Research Inc | Rnaウイルスが導入された樹状細胞を含む抗癌剤 |
JP5296983B2 (ja) * | 2004-06-24 | 2013-09-25 | 株式会社ディナベック研究所 | Rnaウイルスが導入された樹状細胞を含む抗癌剤 |
US8889118B2 (en) | 2004-06-24 | 2014-11-18 | Dna Vec Research Inc. | Anticancer agent containing dendritic cell having RNA virus transferred thereinto |
JP2011504874A (ja) * | 2007-11-28 | 2011-02-17 | 国立大学法人 東京医科歯科大学 | 内因性カイロミクロンを利用した、標的遺伝子の発現を抑制する核酸のデリバリーシステム |
WO2012147370A1 (ja) * | 2011-04-28 | 2012-11-01 | 国立大学法人山口大学 | ターミネータ配列を含む高発現用リバースプライマー及びリニアdna |
US9796973B2 (en) | 2011-04-28 | 2017-10-24 | Yamaguchi University | Terminator sequence-containing reverse primer for overexpression and linear DNA |
Also Published As
Publication number | Publication date |
---|---|
WO1998006437A3 (en) | 1998-08-27 |
US20080089938A9 (en) | 2008-04-17 |
DE69725878D1 (de) | 2003-12-11 |
CA2264012A1 (en) | 1998-02-19 |
CA2264012C (en) | 2011-04-26 |
US6468986B1 (en) | 2002-10-22 |
US20030185890A1 (en) | 2003-10-02 |
WO1998006437A2 (en) | 1998-02-19 |
US6251433B1 (en) | 2001-06-26 |
ATE252914T1 (de) | 2003-11-15 |
DE69725878T2 (de) | 2004-07-29 |
EP0941122A2 (en) | 1999-09-15 |
US7462592B2 (en) | 2008-12-09 |
EP0941122B1 (en) | 2003-10-29 |
JP2006257088A (ja) | 2006-09-28 |
JP4320054B2 (ja) | 2009-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4320054B2 (ja) | ポリヌクレオチド送達のための組成物および方法 | |
US8569065B2 (en) | Compositions and methods for the delivery of biologically active RNAs | |
US7772201B2 (en) | Highly branched HK peptides as effective carriers of siRNA | |
US7070807B2 (en) | Branched histidine copolymers and methods for using same | |
US20060074045A1 (en) | Vector for transfection of eukaryotic cells | |
US7820624B2 (en) | Peptide ligands | |
US6372720B1 (en) | Liposome fusion and delivery vehicle | |
Kim et al. | Basic peptide system for efficient delivery of foreign genes | |
CA2241923C (en) | Receptor-mediated gene transfer system for targeting tumor gene therapy | |
Min et al. | Gene delivery using a derivative of the protein transduction domain peptide, K-Antp | |
US20070098702A1 (en) | Recombinant protein polymer vectors for systemic gene delivery | |
WO2007061762A2 (en) | Non-viral gene delivery complex | |
US20070264191A1 (en) | Materials and Methods Relating to the Treatment of Glioblastomas | |
MXPA01012802A (es) | Copolimeros para el transporte de acidos nucleicos a las celulas. | |
RU2408607C2 (ru) | Способ направленной доставки днк в опухолевые и стволовые клетки | |
WO1997041243A9 (en) | A cytoplasmic gene expression system which utilizes a prokaryotic rna polymerase autogene | |
JP2007514429A (ja) | 細胞表面に連結され得る物質を連結するためのアダプター | |
RU2537262C2 (ru) | Молекулярные конъюгаты с поликатионным участком и лигандом для доставки в клетку и ядро клетки днк и рнк | |
EP1178117A1 (en) | Targeting through integrins | |
JP2001309790A (ja) | 腫瘍指向性ペプチドベクター | |
EP1132099A1 (en) | Nucleic acid transporters and medicinal compositions for gene therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050927 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051226 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060327 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20000913 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080318 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080610 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080724 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20090129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090414 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090519 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090601 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120605 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120605 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130605 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |